Eplivanserin
Sign in to saveAlso known as SR-46,349, Ciltyri
Eplivanserin, also known by its former developmental code names SR-46349 and SR-46615 and by its former tentative brand names Ciltyri and Sliwens, is a serotonin 5-HT2A receptor antagonist which was under development by Sanofi Aventis for the treatment of a variety of medical conditions but was never marketed. It is taken orally.
In the Vinony graph
Vinony's link graph records 1,374 inbound references to Eplivanserin, and connects out to N-methylserotonin, United States Food and Drug Administration and biological half-life.
It sits within the topics 2-Fluorophenyl compounds, 4-Hydroxyphenyl compounds and 5-HT2A antagonists.
Vinony links it to 5 Wikipedia language editions.
Wikidata facts
- Mass
- 328.158706132
Show 3 more facts
- chemical formula
- C₁₉H₂₁FN₂O₂
- canonical SMILES
- CN(C)CCON=C(C=CC1=CC=C(C=C1)O)C2=CC=CC=C2F
- isomeric SMILES
- CN(C)CCO/N=C(/C=C/C1=CC=C(C=C1)O)\C2=CC=CC=C2F
Sources (2)
via Wikidata · CC0
~3 min read
Encyclopedic overview
9 sectionsContents
- Pharmacology
- Pharmacodynamics
- Pharmacokinetics
- Chemistry
- Synthesis
- History
- Research
- See also
- References
Eplivanserin, also known by its former developmental code names SR-46349 and SR-46615 and by its former tentative brand names Ciltyri and Sliwens, is a serotonin 5-HT2A receptor antagonist which was under development by Sanofi Aventis for the treatment of a variety of medical conditions but was never marketed. It is taken orally.
==Pharmacology== ===Pharmacodynamics=== Eplivanserin is an inverse agonist on the serotonin receptor subtype 5-HT2A. In contrast to older sedating drugs acting on 5-HT2A receptors (e.g., mirtazapine, clozapine, risperidone), eplivanserin has practically no affinity to dopamine, histamine and adrenergic receptors.
Excerpted from Wikipedia’s “Eplivanserin” article, available under the CC BY-SA 4.0 licence.